Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Oncorus (ONCR) stocks in Canada

Learn how to easily invest in Oncorus stocks.

Oncorus is a biotechnology business based in the US. Oncorus stocks (ONCR.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $12.94 – an increase of 3.33% over the previous week. Oncorus employs 82 staff and has a market cap (total outstanding stock value) of $33.4 million.

How to buy stocks in Oncorus

  1. Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ONCR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of stocks with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Oncorus stock price (NASDAQ:ONCR)

Use our graph to track the performance of ONCR stocks over time.

Oncorus shares at a glance

Information last updated 2022-05-18.
Latest market close$1.24
52-week range$1.03 - $17.79
50-day moving average $1.49
200-day moving average $5.79
Wall St. target price$15.60
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-2.56

Compare stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 6 of 6
Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Young investors 18 to 24 can get free online trades and a $0 annual account fee. Conditions apply.
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99 - $9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
OFFER
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get $500 in commission free trades when you fund your account with a minimum of $10,000. Conditions apply. Ends August 31st, 2022.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy Oncorus stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Oncorus price performance over time

Historical closes compared with the close of $1.24 from 2022-05-20

1 week (2022-05-16) 3.33%
1 month (2022-04-22) -8.15%
3 months (2022-02-23) -44.14%
6 months (2021-11-23) -78.09%
1 year (2021-05-21) -92.33%
2 years (2020-05-19) N/A
3 years (2019-05-19) N/A
5 years (2017-05-19) N/A

Oncorus financials

Gross profit TTM $0
Return on assets TTM -21.11%
Return on equity TTM -48.94%
Profit margin 0%
Book value $5.03
Market capitalisation $33.4 million

TTM: trailing 12 months

Oncorus share dividends

We're not expecting Oncorus to pay a dividend over the next 12 months.

Oncorus overview

Oncorus, Inc. , a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions


Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site